RxDoctor Payments Data

Teresa Hewlett

Adult Health · Oxford, MSNPI 1689915175

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Scilex Pharmaceuticals Inc. at 27.4% of the total.

$1,943in general payments, 2019–2025

Across 110 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$532
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$506
  • Collegium Pharmaceutical, Inc.$257
  • Boston Scientific$177
  • Si-bone, Inc.$126
  • Nevro Corp.$121
  • plus $225 from 10 others

What the payments were for

  • Food & beverage$1,943100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,943 in reported general payments places this provider in the 75th percentile of 93 adult health providers in Mississippi.

See all adult health providers in Mississippi

Medicare billing

Part B allowed, 2024
$195,918
Medicare patients
447
Services billed
2,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate45$36,668
OxycontinOxycodone Hcl34$25,327
MovantikNaloxegol Oxalate49$19,243
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen614$15,458
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen874$15,091
LinzessLinaclotide22$12,710
Gabapentin576$6,375
Tramadol Hcl ErTramadol Hcl92$6,134
Oxycodone Hcl328$5,980
ZtlidoLidocaine16$5,551
Morphine Sulfate ErMorphine Sulfate167$5,340
Pregabalin320$4,620
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl22$2,960
Diclofenac Sodium30$2,361
Buprenorphine Hcl28$2,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$257$36,66845 claims
Redhill Biopharma Inc.Movantik$11$19,24349 claims
Scilex Pharmaceuticals Inc.Ztlido$532$5,55116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 adult health providers in Mississippi.

Other adult health in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →